This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LeJemtel, T. H. Articles by Davolos, D. Search for Related Content PubMed PubMed Citation Articles by LeJemtel, T. H. Articles by Davolos, D. Pubmed/NCBI databases Medline Plus Health Information Heart Failure

Circulation, Vol 59, 1098-1104, Copyright © 1979 by American Heart Association

ARTICLES

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man

TH LeJemtel, E Keung, EH Sonnenblick, HS Ribner, M Matsumoto, R Davis, W Schwartz, AA Alousi and D Davolos

Chronic congestive heart failure not controlled by conventional therapy was treated with intravenous amrinone, a new non-glycosidic, non- catecholamine cardiotonic agent. Eight patients with New York Heart Association functional class III-IV symptoms were hemodynamically monitored. At peak effect, cardiac index (CI) increased from 1.84 +/- 0.32 to 2.74 +/- 0.44 l/min/m2 (mean +/- SD) (p less than 0.001) and left ventricular filling pressure (LVFP) decreased from 25.8 +/- 6.2 to 19.5 +/- 6.8 mm Hg (p less than 0.05), while heart rate and mean aortic blood pressure did not change significantly. Mean endocardial circumferential fiber shortening (mean Vcf), determined by echocardiography, increased from 0.61 +/- 0.27 to 0.89 +/- 0.34 cir/sec (p less than 0.05). The duration of action after bolus infusion varied from 60--90 minutes. During continuous infusion of amrinone, sustained increases in CI and reductions in LVFP, similar to those at the time of peak effect after bolus administration, were maintained for 180 minutes. These marked cardiotonic effects of amrinone in patients already taking digitalis for severe heart failure occurred without side effects of arrhythmias or altered arterial pressures. The fact that the drug is orally active makes amrinone a v:ry promising inotropic agent for the treatment of chronic heart failure in man.

This article has been cited by other articles:

				M. Azuma, M. Yamane, K. Tachibana, Y. Morimoto, and O. Kemmotsu Effects of epinephrine and phosphodiesterase III inhibitors on bupivacaine-induced myocardial depression in guinea-pig papillary muscle Br. J. Anaesth., January 1, 2003; 90(1): 66 - 71. [Abstract] [Full Text] [PDF]

				A. Uemura, Y. Fujii, and H. Toyooka Inhaled olprinone improves contractility of fatigued canine diaphragm Br. J. Anaesth., March 1, 2002; 88(3): 408 - 411. [Abstract] [Full Text] [PDF]

				Y. Fujii, T. Hoshi, and H. Toyooka Colforsin Daropate Improves Contractility in Fatigued Canine Diaphragm Anesth. Analg., March 1, 2001; 92(3): 762 - 766. [Abstract] [Full Text] [PDF]

				Y Fujii and H Toyooka Different effects of olprinone on contractility in nonfatigued and fatigued diaphragm in dogs Can J Anesth, December 1, 2000; 47(12): 1243 - 1248. [Abstract]

				A. K. Pridjian, E. D. Frohlich, C. H. VanMeter, P. M. McFadden, and J. L. Ochsner Pharmacologic Support With High-Energy Phosphate Preservation in the Postischemic Neonatal Heart Ann. Thorac. Surg., June 1, 1995; 59(6): 1435 - 1440. [Abstract] [Full Text]